Publication of Circular | 06-Jun-2024 | 16:37 | RNS |
Results of placing and subscription | 05-Jun-2024 | 16:04 | RNS |
Proposed Placing, Subscription and Open Offer | 05-Jun-2024 | 07:00 | RNS |
Preliminary Results | 05-Jun-2024 | 07:00 | RNS |
New commercial agreement with large pharma | 03-May-2024 | 07:00 | RNS |
New commercial agreement with AstraZeneca | 24-Apr-2024 | 07:00 | RNS |
US and EU patents for innovative CellKeep™... | 22-Apr-2024 | 07:00 | RNS |
Standard form for notification of major holdings | 10-Jan-2024 | 12:57 | RNS |
Breakthrough clinical results | 04-Jan-2024 | 07:00 | RNS |
Contract announcement with Eisai Inc. | 02-Jan-2024 | 07:00 | RNS |
Broker Announcement | 11-Dec-2023 | 07:00 | RNS |
Trading and business update | 09-Nov-2023 | 07:00 | RNS |
Interim Results for the period ended 30 June 2023 | 07-Sep-2023 | 07:00 | RNS |
ANGLE notice of interim results | 15-Aug-2023 | 07:00 | RNS |
Result of 2023 Annual General Meeting | 28-Jun-2023 | 16:54 | RNS |
Currency | UK Pounds |
Share Price | 13.63p |
Change Today | -0.38p |
% Change | -2.68 % |
52 Week High | 31.35 |
52 Week Low | 9.24 |
Volume | 740,937 |
Shares Issued | 319.08m |
Market Cap | £43.47m |
RiskGrade | 312 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 1 |
Buy | 0 |
Neutral | 0 |
Sell | 0 |
Strong Sell | 0 |
Total | 1 |
No dividends found |
Time | Volume / Share Price |
12:41 | 50 @ 14.00p |
12:39 | 19,834 @ 13.89p |
12:15 | 13,500 @ 13.78p |
11:37 | 357 @ 14.00p |
11:36 | 10,000 @ 13.78p |
CEO | Andrew D Newland |
Finance Director | Ian F Griffiths |
Chair | Jan Groen |
You are here: research